Nature Reviews Drug Discovery 16, 843–862 (2017)
In the version of this article that was originally published, there was an error in Figure 3 on page 847. In this figure, the structure attributed to the compound BMS-986165 is incorrect and the correct structure for this compound has not yet been disclosed. This error has now been corrected in the online version of the article, and the structure of SAR-20347 has been added instead. We apologize for any inconvenience that this error may have caused.
Additional information
The online version of the original article can be found at 10.1038/nrd.2017.201
Rights and permissions
About this article
Cite this article
Schwartz, D., Kanno, Y., Villarino, A. et al. Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 17, 78 (2018). https://doi.org/10.1038/nrd.2017.267
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.267
This article is cited by
-
Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokines
Scientific Reports (2024)
-
Vascular smooth muscle cells enhance immune/vascular interplay in a 3-cell model of vascular inflammation
Scientific Reports (2023)
-
Increased risk of herpes zoster with tofacitinib treatment in Korean patients with rheumatoid arthritis: a single-center prospective study
Scientific Reports (2023)
-
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
Nature Reviews Drug Discovery (2023)
-
Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline
Drugs (2023)
